Takeda Pharmaceutical Company Limited

Facet Biotech Corporation

Werewolf Therapeutics, Inc.

Xoma (us) LLC

Pdl Biopharma, Inc.

Abbott Biotherapeutics Corp.

Xoma Technology Ltd.

Xoma Corporation

Abbvie Biotherapeutics Inc.

Vinay Bhaskar

Mary Haak-Frendscho

Vanitha Ramakrishnan

Kathleen Ann Elias

Gregory M Landes

Wouter Korver

Andrew Walling Drake

David Powers

Shweta Singh

Gyorgy Pal Snell

Debbie Law

Luke Evnin

William Winston

Cynthia Seidel-Dugan

Heather R Brodkin

Jose Andres Salmeron Garcia

Patrick A Baeuerle

Daniel Hicklin

Richard Murray

Daniel E Afar

Mark Leslie White

Ingrid W Caras

Susan R Watson

Agustin De La Calle

Robert B Dubridge

Qi S Wang

Holger Wesche

John Corbin

Dale E Johnson

Ursula Jeffry

Erin Willert

Giselle Knudsen

Daniel J Hicklin

Shuoyen Jack Lin

Shewta Singh

Sun Ho

Qi Wang

Ingrid Caras

Heather Brodkin

Patrick Baeuerle

Antibodies that modulate insulin receptor signaling are provided.

Modulators

Provided in this disclosure are anti-CD38 binding domains, a composition comprising the anti-CD38 binding domains, nucleic acids encoding the anti-CD38 binding domains, and a method of using the anti-CD38 binding domains or the composition for treating multiple myeloma.

Anti-CD38 binding domains

The disclosure features fusion proteins that are conditionally active variants of IL-12. In one aspect, the full-length polypeptides of the invention have reduced or minimal cytokine-receptor activating activity even though they contain a functional cytokine polypeptide. Upon activation, e.g., by cleavage of a linker that joins a blocking moiety, e.g., a steric blocking polypeptide, in sequence to the active cytokine, the cytokine can bind its receptor and effect signaling.

Activatable interleukin 12 polypeptides and methods of use thereof

Isolated antibodies that bind to human CD38 and cynomolgus CD38 are disclosed. Also disclosed are pharmaceutical compositions comprising the disclosed antibodies, and therapeutic and diagnostic methods for using the disclosed antibodies.

Anti-CD38 antibodies

The disclosure features fusion proteins that are conditionally active variants of IL-2. In one aspect, the full-length polypeptides of the invention have reduced or minimal cytokine-receptor activating activity even though they contain a functional cytokine polypeptide. Upon activation, e.g., by cleavage of a linker that joins a blocking moiety, e.g., a steric blocking polypeptide, in sequence to the active cytokine, the cytokine can bind its receptor and effect signaling.

Activatable interleukin-2 polypeptides and methods of use thereof

Provided herein are separation moieties that are suitable for use in conjunction with a variety of therapeutic payloads. The separation moieties serve to generate conditionally active macromolecules whereby the macromolecules have reduced or minimal biological activity until the separation moieties are modified under specific conditions.

Separation moieties and methods of use thereof

Activatable interleukin 12 polypeptides

Activatable interleukin-2 polypeptides

Growing community of inventors

San Francisco, CA, United States of America

Vinay Bhaskar